RESUMO
PURPOSE: Remote monitoring of cardiac implantable electronic devices has been demonstrated to safely reduce frequency of hospital visits. Limited studies are available evaluating the economic impact. The aim of this article is to highlight the social impact and costs for the patients associated with hospital visits for routine device follow-up at the enrollment visit for the TARIFF study (NCT01075516). METHODS: TARIFF is a prospective, cohort, observational study designed to compare the costs and impact on quality of life between clinic-based and remote care device follow-up strategies. RESULTS: Two hundred nine patients (85.2 % males) were enrolled in the study; 153 patients (73.2 %) were retired, 36 (17.2 %) were active workers, 18 (8.6 %) were housewives, and 2 (1.0 %) were looking for a job. Among active workers, 63.9 % required time off from work to attend the hospital visit, while 67.0 % of all patients had to interrupt daily activities. The majority of patients spent half a day or more attending the visit. A carer accompanied 77 % of patients. Among carers, 36.6 % required time off from work, and 77.6 % had to interrupt daily activities. Median distance traveled was 36 km. The average cost of travel was 10 euros with 25 % of patients spending more than 30 euros. CONCLUSIONS: Data from patients enrolled in the TARIFF registry confirm that there are social and economic impacts to patients attending routine device checks in hospital which can be significantly reduced by using a remote monitoring strategy.
Assuntos
Efeitos Psicossociais da Doença , Desfibriladores Implantáveis/economia , Desfibriladores Implantáveis/psicologia , Custos de Cuidados de Saúde/estatística & dados numéricos , Ambulatório Hospitalar/economia , Qualidade de Vida , Telemedicina/economia , Distribuição por Idade , Idoso , Estudos de Coortes , Desfibriladores Implantáveis/estatística & dados numéricos , Emprego/economia , Emprego/psicologia , Emprego/estatística & dados numéricos , Feminino , Seguimentos , Humanos , Itália/epidemiologia , Masculino , Ambulatório Hospitalar/estatística & dados numéricos , Distribuição por Sexo , Telemedicina/estatística & dados numéricos , Viagem/economia , Viagem/psicologia , Viagem/estatística & dados numéricosRESUMO
AIMS: The aims of the study are to develop a cost-minimization analysis from the hospital perspective and a cost-effectiveness analysis from the third payer standpoint, based on direct estimates of costs and QOL associated with remote follow-ups, using Merlin@home and Merlin.net, compared with standard ambulatory follow-ups, in the management of ICD and CRT-D recipients. METHODS AND RESULTS: Remote monitoring systems can replace ambulatory follow-ups, sparing human and economic resources, and increasing patient safety. TARIFF is a prospective, controlled, observational study aimed at measuring the direct and indirect costs and quality of life (QOL) of all participants by a 1-year economic evaluation. A detailed set of hospitalized and ambulatory healthcare costs and losses of productivity that could be directly influenced by the different means of follow-ups will be collected. The study consists of two phases, each including 100 patients, to measure the economic resources consumed during the first phase, associated with standard ambulatory follow-ups, vs. the second phase, associated with remote follow-ups. CONCLUSION: Remote monitoring systems enable caregivers to better ensure patient safety and the healthcare to limit costs. TARIFF will allow defining the economic value of remote ICD follow-ups for Italian hospitals, third payers, and patients. The TARIFF study, based on a cost-minimization analysis, directly comparing remote follow-up with standard ambulatory visits, will validate the cost effectiveness of the Merlin.net technology, and define a proper reimbursement schedule applicable for the Italian healthcare system. TRIAL REGISTRATION: NCT01075516.
Assuntos
Dispositivos de Terapia de Ressincronização Cardíaca/economia , Terapia de Ressincronização Cardíaca/economia , Desfibriladores Implantáveis/economia , Cardioversão Elétrica/economia , Custos de Cuidados de Saúde , Monitorização Ambulatorial/economia , Projetos de Pesquisa , Telemedicina/economia , Telemetria/economia , Assistência Ambulatorial/economia , Terapia de Ressincronização Cardíaca/efeitos adversos , Dispositivos de Terapia de Ressincronização Cardíaca/efeitos adversos , Distribuição de Qui-Quadrado , Redução de Custos , Análise Custo-Benefício , Desfibriladores Implantáveis/efeitos adversos , Cardioversão Elétrica/efeitos adversos , Cardioversão Elétrica/instrumentação , Custos Hospitalares , Humanos , Reembolso de Seguro de Saúde , Itália , Modelos Econômicos , Monitorização Ambulatorial/instrumentação , Valor Preditivo dos Testes , Estudos Prospectivos , Qualidade de Vida , Sistema de Registros , Telemedicina/instrumentação , Telemetria/instrumentação , Fatores de Tempo , Resultado do TratamentoRESUMO
INTRODUCTION: Patients with pacemakers and implantable defibrillators (ICD) may experience asymptomatic atrial fibrillation (AF), detected with a delay depending on the in-person follow-up schedule. Home monitoring (HM) remote control with automatic alerts for AF may drive early anticoagulation, potentially reducing stroke risk. METHODS AND RESULTS: A sample of 136 pacemaker (103) and ICD (33) patients with or without cardiac resynchronization therapy not taking anticoagulation at implant were monitored remotely with HM. Upon HM alerts for AF, patients were recalled to update therapy. Two-year data were entered in a computer Monte Carlo model, simulating 4,000 virtual subjects with the same AF and CHADS(2) stroke risk distribution of our real population. Simulations reproduced a 2-year follow-up. Two thousand subjects were supposed to be followed with HM (HM group) and 2,000 with standard in-person follow-up (SF group) at 3, 6, 9, or 12 months. Two-year Kaplan-Meier cumulative probability of >/=24-hour AF was 15.6% (95%CI 8.5-23.3%); the AF-related symptom rate was 27% and the median CHADS(2) score was 2. As a result of simulations, stroke incidence in case of AF was 2.3 +/- 1.1% in the HM group and 2.4 +/- 1.1%, 2.5 +/- 1.2%, 2.7 +/- 1.2%, and 2.9 +/- 1.3% in the SF group with 3-, 6-, 9-, and 12-month follow-up programs, with odds ratios of 0.97 (95%CI 0.93-1.01), 0.91 (0.88-0.95), 0.87 (0.84-0.90), and 0.82 (0.79-0.85) (HM better if odds ratios <1), respectively. CONCLUSIONS: Daily HM potentially reduces the stroke risk by 9% to 18% with respect to SF with intervisit intervals of 6 to 12 months.